Comparison between ATLL patients and non-ATLL patients was carried out for each variable (Table 1) . Gender, age, disease status, conditioning regimen, steroid usage and incidence of CMV disease were estimated according to the Mann-Whitney U-test, while stem cell source, GVHD prophylaxis and CMV-IgG serostatus were estimated using Fisher's exact test. A disease status of high risk was defined as not in CR (non-CR) for all hematological malignant diseases and in high risk of myelodysplastic syndrome as defined by the International Prognostic Scoring System. All other disease statuses were defined as standard risk. For the risk evaluation of CMV infection, patient group with CMV-IgG serostatus of donor − /recipient − was considered as low risk, and all others were defined as high risk status. The probability of CMV infection was estimated based on cumulative incidence curves. The competing event was death without CMV infection. The groups were compared using Gray's test. The Fine-Gray proportional hazards model was used to determine the significance of multivariables in determining the incidence of CMV infection. Statistical significance was defined as Po0.05.
Twenty-three ATLL patients and 29 non-ATLL patients (of which 12 had AML, 10 myelodysplastic syndrome, 3 non-Hodgkin lymphoma, 2 had ALL, 1 aplastic anemia and 1 multiple myeloma) were included in our study. No patient received ganciclovir or Foscavir as prophylaxis. Median age at allogeneic HSCT was 54 years (range 19-69). Thirteen patients were transplanted from sibling donors (of which 6 were BM and 7 peripheral blood) and 39 patients from unrelated donors (of which 31 were BM and 8 umbilical cord blood). Thirty-eight patients had received a myeloablative conditioning regimen and 14 a reduced intensity conditioning regimen (RIC) before allogeneic HSCT ( Table 1 ). All of the recipients of sibling donor transplants received CsA and shortterm MTX as the GVHD prophylaxis. Tacrolimus and short-term MTX were administered in all of the unrelated BM recipients. With respect to GVHD, 15 patients suffered any grade of GVHD. Twelve of 15 patients were grade II-IV and 5 were grade III-IV. In addition, tacrolimus and mycophenolate mofetil were administered to all of the umbilical cord blood recipients except one who received tacrolimus alone. The details of CMV-IgG serostatus are described in Table 1 . Thirty of 52 patients received steroids within 10 days before the incidence of CMV infection, including 16 patients who received over 1 mg/kg steroid for GVHD treatment and the remaining 14 patients received low-dose steroid for not only GVHD treatment, but also prophylaxis for fever and drug allergies (Table 1) . Five patients developed CMV diseases (4 colitis and 1 pneumonia) and no significant difference was observed between ATLL and non-ATLL patients (Table 1) .
Thirty-nine patients (20 ATLL and 19 non-ATLL) were diagnosed with CMV infection. The probability of CMV infection was 87% in ATLL patients compared with 68.9% in non-ATLL patients (P = 0.004), 87.9% in age ⩾ 50 years vs 52.6% in o 50 years (P = 0.021), 93.8% in steroid-users of a dose of over 1 mg/day vs 68.2% in others (P = 0.001), 93.3% in steroid-users in any dose of steroid vs 52.2% in non-users (Po 0.001) and 100% in RIC vs 66.5% in myeloablative conditioning regimen (P = 0.001). In the multivariate analysis, ATLL (HR: 3.696, 95% CI: 1.535-8.898; P = 0.004), steroid usage (HR: 3.683, 95% CI: 1.297-10.46; P = 0.014) and RIC (HR: 2.394, 95% CI: 1.100-5.212; P = 0.028) were the significant factors for occurrence of CMV infection ( Table 2) .
The incidence of CMV infection was high in allogeneic HSCT recipients with ATLL compared with non-ATLL patients in our study. Ogata et al. 5 previously reported that CMV reactivation was common in ATLL patients receiving chemotherapy. With respect to the relationship between age and serostatus, although only 6 of 12 non-ATLL recipients whose ages were o 50 years, were seropositive, all of the same group of ATLL recipients were seropositive before transplantation. These results indicated that ATLL patients typically have a CMV-compromised immune system. In our study, there was no difference in incidence of CMV diseases between ATLL patients and non-ATLL patients. This result might indicate that preemptive therapy based on monitoring CMV pp65 antigenemia test successfully prevented HSCT recipients from contracting CMV diseases in both the groups.
RIC regimens were a significant factor for incidence of CMV infection, which was a different result from previous reports. 6, 7 There is a possibility that the remaining infected lymphocytes after RIC are responsible for CMV infection after transplantation.
Previous reports showed that steroid administration is a risk factor for CMV infection. 8 Despite no significant difference being observed between steroid usage in ATLL patients and non-ATLL patients, usage of steroid was a significant factor in our study. Therefore, although the limitation of this study is the small number of patients, ATLL could be one of the disease-specific risk factors for CMV infection. Abbreviations: ATLL = adult T-cell leukemia/lymphoma; MAC = myeloablative conditioning regimen; MMF = mycophenolate mofetil; RIC = reduced intensity conditioning regimen; sMTX = short-term MTX; Sib = sibling; TAC = tacrolimus; UCB = umbilical cord blood; UBM = unrelated BM. Comparison among groups was carried out in each item. ATLL patients showed dominantly high-risk disease status compared with non-ATLL patients. Abbreviations: ATLL = adult T-cell leukemia/lymphoma; CI = confidence interval; CB = cord blood; RIC = reduced intensity conditioning regimen. Multivariate analysis for the incidence of CMV infection was carried out with the Fine-Gray proportional hazard model. ATLL and steroid usage were the significant factors for the incidence of CMV infection. The results with statistical significance were highlighted in bold.
